Efforts to develop genetic therapies are ongoing, including a recent gene therapy study in which an Atp1a3 D801N mouse model of AHC was treated with an AAV9-delivered ATP1A3 transgene. This evidence concerns the gene ATP1A3 and alternating hemiplegia of childhood.